24,070 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by Capstone Investment Advisors LLC

Capstone Investment Advisors LLC bought a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 24,070 shares of the biotechnology company's stock, valued at approximately $625,000.

A number of other institutional investors also recently bought and sold shares of the stock. CreativeOne Wealth LLC bought a new stake in Exelixis during the third quarter valued at about $203,000. Brooklyn Investment Group bought a new stake in Exelixis during the third quarter valued at about $42,000. Quantbot Technologies LP bought a new stake in Exelixis during the third quarter valued at about $149,000. FMR LLC raised its holdings in Exelixis by 6.1% during the third quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company's stock valued at $63,891,000 after acquiring an additional 140,568 shares during the period. Finally, Bank of Montreal Can raised its holdings in Exelixis by 51.5% during the third quarter. Bank of Montreal Can now owns 104,385 shares of the biotechnology company's stock valued at $2,710,000 after acquiring an additional 35,496 shares during the period. 85.27% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on EXEL. Guggenheim raised their price target on Exelixis from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. The Goldman Sachs Group upgraded Exelixis to a "strong sell" rating in a research report on Tuesday, October 15th. Wells Fargo & Company raised their price objective on Exelixis from $32.00 to $36.00 and gave the company an "overweight" rating in a research report on Wednesday, October 30th. JMP Securities restated a "market outperform" rating and set a $29.00 price objective on shares of Exelixis in a research report on Friday, October 11th. Finally, UBS Group began coverage on Exelixis in a research report on Thursday, September 19th. They set a "neutral" rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $31.44.

Insider Activity

In other news, EVP Dana Aftab sold 1,162 shares of Exelixis stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total transaction of $36,486.80. Following the completion of the sale, the executive vice president now owns 498,945 shares of the company's stock, valued at approximately $15,666,873. The trade was a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Patrick J. Haley sold 41,588 shares of the business's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $34.36, for a total transaction of $1,428,963.68. Following the completion of the transaction, the executive vice president now directly owns 288,665 shares of the company's stock, valued at $9,918,529.40. This trade represents a 12.59 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 279,736 shares of company stock valued at $9,308,410. Corporate insiders own 2.85% of the company's stock.

Exelixis Price Performance

Shares of NASDAQ:EXEL traded up $0.53 during trading hours on Friday, hitting $36.46. 1,691,874 shares of the company's stock traded hands, compared to its average volume of 2,070,603. Exelixis, Inc. has a 1 year low of $19.20 and a 1 year high of $36.97. The business has a fifty day moving average price of $30.82 and a 200-day moving average price of $26.08. The firm has a market capitalization of $10.41 billion, a P/E ratio of 23.37, a price-to-earnings-growth ratio of 0.90 and a beta of 0.51.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business had revenue of $539.50 million during the quarter, compared to analyst estimates of $490.31 million. During the same quarter in the previous year, the business earned $0.10 earnings per share. The company's revenue for the quarter was up 14.3% compared to the same quarter last year. As a group, equities analysts predict that Exelixis, Inc. will post 1.69 earnings per share for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.